UPDATE: Citi Initiates Coverage on Supernus Pharmaceuticals

by Benzinga Staff
May 29, 2012 8:46 AM | 24 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

According to a research report published this morning, Citi has initiated Supernus Pharmaceuticals (NASDAQ: SUPN) with a Neutral rating and $6 PT.In the report, Citi said, "Our PT is based on a DCF value of $6/share. Our upside & downside Trokendi market share scenarios show a DCF value of >$9 & >$3, respectively. Our High Risk rating reflects the need for additional capital to execute its commercial plans on its extended release (ER) AED's."Supernus Pharmaceuticals closed Friday at $5.98.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorInitiationAnalyst RatingsCiti

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.